Stablix, Inc.

Pioneering transformative medicines for targeted deubiquitination therapeutics (TPT)

[Stablix, Inc. @StablixInc]

Check out the @WuXi_AppTec “BOLD: Innovation That Matters” event happening today.

Hear from our CSO @EddineSaiah on how we’re expanding the definition of druggability by unlocking the power of targeted protein #deubiquination.

Tune in: https://t.co/3qCDKwhNmT

#TakingBOLDAction

[Stablix, Inc. @StablixInc]

How are we #TakingBOLDAction to pioneer targeted protein #deubiquitination therapeutics?

Tomorrow, Chief Scientific Officer @EddineSaiah will share how we're aiming to redefine #druggability during @WuXi_AppTec’s “BOLD: Innovation That Matters." Register: https://t.co/3qCDKwhNmT

[Stablix, Inc. @StablixInc]

Why is our collaboration with @VertexPharma the perfect match? Our CEO, Tony Kingsley, explains:

“We bring DUB biology and chemistry, they bring the target disease and disease expertise.”

Check out the full article by @Nicole_DeFeudis of @endpts here! 👇
https://t.co/ABUxb3Gfoi

[Stablix, Inc. @StablixInc]

We’re thrilled to announce our collaboration with @VertexPharma to discover & develop #TPS (targeted protein stabilization) therapeutics.

Learn how we’re exploring the potential of targeted protein #deubiquitination for patients in need of breakthroughs: https://t.co/mDikkHcsXs

[Stablix, Inc. @StablixInc]

Our COO and co-founder, Kevin Sprott, is thrilled to speak in a panel discussion at the #wellsfargo 2023 Targeted Protein Degradation (#TPD) Virtual Summit tomorrow (2p EST), as we establish a new paradigm for restoring protein function. https://t.co/k95kbmQaU6

[Stablix, Inc. @StablixInc]

@jaybradner @DanNomura @UCBerkeley @nchembio Great work highlighting the potential of #TPS. Exciting times ahead for this emerging modality! #inducedproximity https://t.co/U541AWDsIF

[Stablix, Inc. @StablixInc]

@DanNomura @nchembio @n_j_henning @lydiaboike @UCB_Chemistry @NovartisScience @TheMarkFdn Great to see the @DanNomura lab highlight the promise of #TPS to treat disease. Exciting times ahead for this emerging field! https://t.co/U541AWDsIF

[Stablix, Inc. @StablixInc]

Exciting start to the week. We are thrilled to welcome Tony Kingsley!

[Endpoints News @endpts]

Tony Kingsley is taking charge at Stablix, a biotech startup out of Versant that announced a $63 million launch raise just a couple of months before the biotech exec found the exit at Scholar Rock.

https://t.co/3d5FskEsXF

[Lisa Jarvis @lisamjarvis]

Versant-backed Stablix has launched to use heterobifunctional moecules to tap into the ubiquitin-proteasome system--but they're not crunching down proteins, they're trying to restore their function. My story: https://t.co/nBvWl1WGcp

[Stablix, Inc. @StablixInc]

We are excited to announce our Series A launch to pioneer this new therapeutic white space and address a number of devastating diseases! #targetedproteinstabilization #stablix #TPS
https://t.co/RieJDUk2Tp